CD158 Receptor Controls Cytotoxic T-Lymphocyte Susceptibility to Tumor-Mediated Activation-Induced Cell Death by Interfering with Fas Signaling

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7475-7482

  Gati, Asma ^a   Guerra, Nadia ^a   Gaudin, Catherine ^a   Da Rocha, Sylvie ^a   Escudier, Bernard ^b   Lécluse, Yann ^c   Bettaieb, Ali ^d   Chouaib, Salem ^a   Caignard, Anne ^a,d  

^a Inst Federatif de Rech 69   (France)

^b Unite des Therapies Innovantes   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CD158 RECEPTOR; CD8 ANTIGEN; FAS ANTIGEN; FAS LIGAND; HLA ANTIGEN; HLA CW4 ANTIGEN; IMMUNOGLOBULIN LIKE RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY CD3; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL FUNCTION; CELL INFILTRATION; CELL INTERACTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; GENE INDUCTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KILLER CELL; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD3; ANTIGENS, CD95; CARCINOMA, RENAL CELL; CELL DEATH; DOWN-REGULATION; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0242694876     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Nathan, P., and Eisen, T. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol., 3: 89-96, 2002.
2. Uzzo, R., Clark, P., Rayman, P., Bloom, T., Rybicki, L., Novick, A., Bukowski, R., and Finke, J. Alterations in NFκB activation in T lymphocytes of patients with renal cell carcinoma. J. Natl. Cancer Inst. (Bethesda), 91: 718-721, 1999.
3. Uzzo, R., Kolenko, V., Froelich, C., Tannenbaum, C., Molto, L., Novick, A., Bander, N., Bukowski, R., and Finke, J. The T cell death knell: immune-mediated tumor death in renal cell carcinoma. Clin. Cancer Res., 7: 3276-3281, 2001.
4. Guerra, N., Guillard, M., Angevin, E., Echchakir, H., Escudier, B., Moretta, A., Chouaib, S., and Caignard, A. Killer inhibitory receptor (CD 158b) modulates the lytic activity of tumor specific T lymphocytes infiltrating renal cell carcinoma. Blood, 95: 2883-2889, 2000.
5. Gati, A., Guerra, N., Giron-Michel, J., Azzarone, B., Angevin, E., Moretta, A., Chouaib, S., and Caignard, A. Tumor cells regulate the lytic activity of tumor-specific cytotoxic T lymphocytes by modulating the inhibitory natural killer receptor function. Cancer Res., 61: 3240-3244, 2001.
6. Binstadt, B. A., Brumbaugh, K. M., Dick, C. J., Scharenberg, A. M., Williams, B. L., Colonna, M., Lanier, L. L., Kinet, J. P., Abraham, R. T., and Leibson, P. J. Sequential involvement of Lck and SHP-1 with MHC recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. Immunity, 5: 629-638, 1996.
7. Long, E. O. Regulation of immune responses by inhibitory receptors. Adv. Exp. Med. Biol., 452: 19-28, 1998.
8. Vitale, M., Sivori, S., Pende, D., Augugliaro, R., Donato, C. D., Amoroso, A., Malnati, M., Bottino, C., Moretta, L., and Moretta, A. Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class 1: their role in the definition of different groups of alloreactive NK cell clones. Proc. Natl. Acad. Sci. USA. 93: 1453-1457, 1996.
9. Mingari, M. C., Ponte, M., Vitale, C., Bellomo, R., and Moretta, L. Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum. Immunol., 61: 44-50, 2000.
10. Ferrini, S., Cambiaggi, A., Meazza, R., Sforzini, S., Marciano, S., Mingari. M. C., and Moretta, L. T cell clones expressing the natural killer cell related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function. Eur. J. Immunol., 24: 2294-2298, 1994.
11. Phillips, J. H., Gumperz, J. E., Parham, P., and Lanier, L. L. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science (Wash. DC), 268: 403-405, 1995.
12. Mingari, M. C., Schiavetti, F., Ponte, M., Vitale, C., Maggi, E., Romagnani, S., Demarest, J., Pantaleo, G., Fauci, A. S., and Moretta, L. Human CD8+T lymphocyte subsets that express HLA class I specific inhibitory receptors represent oligoclonally or monoclonally expanded populations. Proc. Natl. Acad. Sci. U S A, 93: 12433-12438, 1996.
13. Young, N., Uhrberg, M., Phillips, J., Lanier, L., and Parham, P. Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J. Immunol., 166: 3933-3941, 2001.
14. Ugolini, S., Arpin, C., Anfossi, N., Walzer, T., Cambiaggi, A., Forster, R., Lipp, M., Toes, R., Melief, C., Marvel, J., and Vivier, E. Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. Nat. Immunol., 2: 430-435, 2001.
15. Speiser, D., Miranda, R., Zakarian, A., Bachmann, M., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R., and Ohashi, P. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med., 186: 645-653, 1997.
16. Lee, P., Yee, C., Savage, P., Fong, L., Brockstedt, D., Weber, J., Johnson, D., Swetter, S., Thompson, J., Greenberg, P., Roederer, M., and Davis, M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5: 677-685, 1999.
17. Hildeman, D., Zhu, Y., Mitchell, T., Kappler, J., and Marrack, P. Molecular mechanisms of activated T cell death in vivo. Curr. Opin. Immunol., 14: 354-359, 2002.
18. Budd, R. Activation-induced cell death. Curr. Opin. Immunol., 13: 356-362, 2001.
19. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K., Debatin, K., Krammer, P., and Peter, M. Two CD95 (APO-I/Fas) signaling pathways. EMBO J., 17: 1675-1687, 1998.
20. Medema, J., and Borst, J. T cell signaling: a decision of life and death. Hum. Immunol., 60: 403-411, 1999.
21. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L., and Tschopp, J. Inhibition of death receptor signals by cellular FLIP. Nature (Lond.), 388: 190-195, 1997.
22. Guerra, N., Michel, F., Gati, A., Gaudin, C., Mishal, Z., Escudier, B., Acuto, O., Chouaib, S., and Caignard, A. Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction. Blood, 100: 2874-2881, 2002.
23. Chang, D., Xing, Z., Pan, Y., Algeciras-Schimnich, A., Barnhart, B., Yaish-Ohad, S., Peter, M., and Yang, X. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J., 21: 3704-3714, 2002.
24. Sprent, J., and Surh, C. T cell memory. Annu. Rev. Immunol., 20: 551-579, 2002.
25. Lanzavecchia, A., and Sallusto, F. Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol., 12: 982-987, 2002.
26. Dhein, J., Walczak, H., Baumler, C., Debatin, K., and Krammer, P. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature (Lond.), 273: 438-441, 1995.
27. Brunner, T., Mogil, R., LaFace, D., Yoo, N., Mahboubi, A., Echeverri, F., Martin, S., Force, W., Lynch, D., Ware, C. F., et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (Lond.), 373: 441-444, 1995.
28. Valmori, D., Scheibenbogen, C., Dutoit, V., Nagorsen, D., Asemissen, A., Rubio-Godoy, V., Rimoldi, D., Guillaume, P., Romero, P., Schadendorf, D., Lipp, M., Dietrich, P., Thiel, E., Cerottini, J., Lienard, D., and Keilholz, U. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res., 62: 1743-1750, 2002.
29. Mailliard, R., and Lotze. M. Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor targets. Clin. Cancer Res., 7: 980-988, 2001.
30. Molldrem, J. J., Lee, P. P., Kant, S., Wieder, E., Jiang, W., Lu, S., Wang, C., and Davis, M. M. Chronic myelogenous leukemia shapes host immunity by selective deletion of high avidity leukemia-specific T cells, J. Clin. Invest., 111: 639-647, 2003.
31. Valitutti, S., Muller, S., Cella, M., Padovan, E., and Lanzavecchia, A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature (Lond.), 375: 148-151, 1995.
32. Somma, M. D., Somma, F., Montani, M., Mangiacasale, R., Cundari, E., and Piccolella, E. TCR engagement regulates differential responsiveness of human memory T cells to Fas (CD95)-mediated apoptosis. J. Immunol., 162: 3851-3858, 1999.
33. Freitas, A., and Rocha, B. Population biology of lymphocytes: the flight for survival. Annu. Rev. Immunol., 18: 83-111, 2000.
34. Grayson, J., Harrington, L., Lanier, J., Wherry, E., and Ahmed, R. Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. J. Immunol., 169: 3760-3770, 2002.
35. Roger, J., Chalifour, A., Lemieux, S., and Duplay, P. Ly49A inhibits TCR/CD3-induced apoptosis and IL-2 secretion. J. Immunol., 167: 6-10, 2001.
36. Chwae, Y., Chang, M., Park, S., Yoon, H., Park, H., Kim, S., and Kim, J. Molecular mechanism of the activation-induced cell death inhibition mediated by a p70 inhibitory killer cell Ig-like receptor in Jurkat T cells. J. Immunol., 169: 3726-3735, 2002.
37. Scaffidi, C., Schmitz, I., Krammer, P., and Peter, M. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem., 274: 1541-1548, 1999.
38. Kirchhoff, S., Muller, W., Li-Weber, M., and Krammer, P. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur. J. Immunol., 30: 2765-2774, 2000.
39. Parijs, L. V., Refaeli, Y., and Abbas, Z. Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes. Immunity., 11: 763-710, 1999.
40. Inaba, M., Kurasawa, K., Mamura, M., Kumano, K., Saito, Y., and Iwamoto, I. Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells. J. Immunol., 163: 1315-1320, 1999.
41. Kirchhoff, S., Muller, W., Krueger, A., Schmitz, I., and Krammer, P. TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity. J. Immunol., 165: 6293-6300, 2000.
42. Zhang, J., Cado, D., Chen, A., Kabra, N., and Winoto, A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature (Lond.), 392: 296-300, 1998.
43. Salmena, L., Lemmers, B., Hakem, A., Matysiak-Zablocki, E., Murakami, K., Au, P., Berry, D., Tamblyn, L. Shehabeldin, A., Migon, E., Wakeham, A., Bouchard, D., Yeh, W., McGlade, J., Ohashi, P., and Hakem, R. Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev., 17: 883-895, 2003.
44. Chun, H., Zheng, L., Ahmad, M., Wang, J., Speirs, C., Siegel, R., Dale, J., Puck, J., Davis, J., Hall, C., Skoda-Smith, S., Atkinson, T., Straus, S., and Lenardo, M. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature (Lond.), 419: 395-399, 2002.
45. Peter, M., Kischkel, F., Scheuerpflug, C., Medema, J., Debatin, K., and Krammer, P. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur. J. Immunol., 27: 1207-1212, 1997.
46. Ducoroy, P., Micheau, O., Perruche, S., Dubrez-Daloz, L., Fornel, D. D., Dutartre, P., Saas, P., and Solary, E. LF 15-0195 immunosuppressive agent enhances activation-induced T-cell death by facilitating caspase-8 and caspase-10 activation at the DISC level. Blood, 101: 194-201, 2003.
47. Su, X., Zhou, T., Yang, P., Wang, Z., and Mountz, J. Hematopoietic cell protein-tyrosine phosphatase-deficient motheaten mice exhibit T cell apoptosis defect. J. Immunol., 156: 4198-4208, 1996.
48. Zhang, J., Somani, A., Watt, S., Mills, G., and Siminovitch, K. The Src-homology domain 2-bearing protein tyrosine phosphatase-1 inhibits antigen receptor-induced apoptosis of activated peripheral T cells. J. Immunol., 162: 6359-6367, 1999.
49. Restifo, N. Countering the "counterattack" hypothesis. Nat. Med., 7: 259-, 2001.
50. Maher, S., Toomey, D., Condron, C., and Bouchier-Hayes, D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol. Cell Biol., 30: 131-137, 2002.
51. Favre-Felix, N., Fromentin, A., Hammann, A., ESolary, Martin, F., and Bonnotte, B. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J. Immunol., 164: 5023-5027, 2000.
52. Romagnani, C., Pietra, G., Falco, M., Millo, E., Mazzarino, P., Biassoni, R., Moretta, A., Moretta, L., and Mingari, M. C. Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. Proc. Natl. Acad. Sci. U S A, 99: 11328-11332, 2002.
53. Pietra, G., Romagnani, C., Falco, M., Vitale, M. Castriconi, R., Pende, D., Millo, E., Anfossi, S., Biassoni, R., Moretta, L., and Mingari, M. C. The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR α/β-mediated recognition. Eur. J. Immunol., 12: 3687-3693, 2001.
54. Moretta, L., Romagnani, C., Pietra, G., Moretta, A., and Mingari, M. NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends Immunol., 24, 136-143, 2003.